Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Overview of attention for article published in Journal of Hematology & Oncology, January 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news: 1 news outlet
policy: 1 policy source

twitter: 6 X users

Citations

dimensions_citation: 45 Dimensions

Readers on

mendeley: 27 Mendeley

Summary News Policy documents X Dimensions citations

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 12,964 followers.

RT @smbenlazar: Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 st…

22 Apr 2021

Reply Repost Favourite

Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002) https://t.co/mlmnast2M4

22 Apr 2021

Reply Repost Favourite

Efficacy and safety of geptanolimab for relapsed or refractory peripheral T cell #lymphoma. https://t.co/gnr8T2xXL3

14 Jan 2021

Reply Repost Favourite

Chinese phase 2 study published in J Hematol Oncol showed promising efficacy of anti-PD-1 antibody geptanolimab in R/R #PTCL #lymsm #immunonc

14 Jan 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.